Justin Stebbing: Was very lucky to be part of a large team that very extensively reviewed the PAM pathway and its importance in cancer.
Quoting Justin Stebbing, on LinkedIn:
“Was very lucky to be part of a large team that very extensively reviewed the PAM pathway and its importance in cancer, not just its importance in cancer metastasis, but in its personalised and precision targeting via existing and new drugs. It’s one of the more important pathways as it’s so commonly dysregulated, but there are lots of interesting trials in the space now with readouts soon.”
For the article click here.
Source: Justin Stebbing/LinkedIn
Justin Stebbing is a visiting Professor of Cancer Medicine and Oncology at Imperial College, London and a Professor of Biomedical Sciences at Anglia Ruskin University (ARU), Cambridge. He was appointed the first NIHR oncology professor in 2011. He is editor-in-chief of Nature’s cancer journal Oncogene. Prof. Stebbing has published over 700 peer-reviewed papers in leading academic journals. He is a member of the American Society for Clinical Investigation, Fellow of the Royal College of Physicians, the Royal College of Pathologists and sits on many advisory boards. He is on the Editorial Board of OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023